{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T15:00:51Z","timestamp":1761490851463,"version":"3.37.3"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,8,28]],"date-time":"2019-08-28T00:00:00Z","timestamp":1566950400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,8,28]],"date-time":"2019-08-28T00:00:00Z","timestamp":1566950400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Boehringer Ingelheim"},{"DOI":"10.13039\/100011713","name":"Worldwide Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011713","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Angiogenesis"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1007\/s10456-019-09677-x","type":"journal-article","created":{"date-parts":[[2019,8,28]],"date-time":"2019-08-28T13:08:29Z","timestamp":1566997709000},"page":"535-546","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Variable impact of three different antiangiogenic drugs alone or in combination with chemotherapy on multiple bone marrow-derived cell populations involved in angiogenesis and immunity"],"prefix":"10.1007","volume":"22","author":[{"given":"Elaine","family":"Reguera-Nu\u00f1ez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shan","family":"Man","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Hilberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6015-2570","authenticated-orcid":false,"given":"Robert S.","family":"Kerbel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,8,28]]},"reference":[{"issue":"23","key":"9677_CR1","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa032691","volume":"350","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and Leucovorin lor metastatic colorectal cancer. N Engl J Med 350(23):2335\u20132342","journal-title":"N Engl J Med"},{"key":"9677_CR2","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1056\/NEJMoa061884","volume":"355","author":"A Sandler","year":"2006","unstructured":"Sandler A, Gray R, Perry MC et al (2006) Paclitaxel\u2013carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542\u20132550","journal-title":"N Engl J Med"},{"key":"9677_CR3","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","volume":"365","author":"TJ Perren","year":"2011","unstructured":"Perren TJ, Swart AM, Pfisterer J et al (2011) A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365:2484\u20132496","journal-title":"N Engl J Med"},{"key":"9677_CR4","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1056\/NEJMoa1309748","volume":"370","author":"KS Tewari","year":"2014","unstructured":"Tewari KS, Sill MW, Long HJ et al (2014) Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med 370:734\u2013743","journal-title":"N Engl J Med"},{"issue":"3","key":"9677_CR5","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/S1470-2045(15)70004-5","volume":"16","author":"RT Penson","year":"2015","unstructured":"Penson RT, Huang HQ, Wenzel LB et al (2015) Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240). Lancet Oncol 16(3):301\u2013311","journal-title":"Lancet Oncol"},{"key":"9677_CR6","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(13)61719-5","volume":"383","author":"CS Fuchs","year":"2014","unstructured":"Fuchs CS, Tomasek J, Yong CJ et al (2014) Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 383:31\u201339","journal-title":"Lancet"},{"key":"9677_CR7","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1126\/science.1104819","volume":"307","author":"R Jain","year":"2005","unstructured":"Jain R (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307:58\u201362","journal-title":"Science"},{"key":"9677_CR8","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.ccr.2008.08.001","volume":"14","author":"Y Shaked","year":"2008","unstructured":"Shaked Y, Henke E, Roodhart JM et al (2008) Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell 14:263\u2013273","journal-title":"Cancer Cell"},{"key":"9677_CR9","first-page":"1011","volume":"2","author":"TJ Abrams","year":"2003","unstructured":"Abrams TJ, Murray LJ, Pesenti E et al (2003) Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with \"standard of care\" therapeutic agents for the treatment of breast cancer. Mol Cancer Ther 2:1011\u20131021","journal-title":"Mol Cancer Ther"},{"key":"9677_CR10","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s00432-007-0247-4","volume":"134","author":"O Gu\u00e9rin","year":"2008","unstructured":"Gu\u00e9rin O, Formento P, Lo Nigro C et al (2008) Supra-additive antitumor effect of sunitinib malate (SU11248, Sutent\u00ae) combined with docetaxel. A new therapeutic perspective in hormone refractory prostate cancer. J Cancer Res Clin Oncol 134:51\u201357","journal-title":"J Cancer Res Clin Oncol"},{"issue":"2","key":"9677_CR11","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1158\/1078-0432.CCR-08-1174","volume":"15","author":"J Ma","year":"2009","unstructured":"Ma J, Waxman D (2009) Dominant effect of antiangiogenesis in combination therapy involving cyclophosphamide and axitinib. Clin Cancer Res 15(2):578\u2013588","journal-title":"Clin Cancer Res"},{"key":"9677_CR12","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1007\/s10637-010-9451-1","volume":"29","author":"EP Hui","year":"2011","unstructured":"Hui EP, Lui VWY, Wong CSC et al (2011) Preclinical evaluation of sunitinib as single agent or in combination with chemotherapy in nasopharyngeal carcinoma. Investig New Drugs 29:1123\u20131131","journal-title":"Investig New Drugs"},{"key":"9677_CR13","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1007\/s12032-011-9905-0","volume":"29","author":"D Wang","year":"2012","unstructured":"Wang D, Jiang Z, Zhang L (2012) Concurrent and sequential administration of sunitinib malate and docetaxel in human non-small cell lung cancer cells and xenografts. Med Oncol 29:600\u2013606","journal-title":"Med Oncol"},{"issue":"9","key":"9677_CR14","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1158\/0008-5472.CAN-12-4183","volume":"73","author":"E Guerin","year":"2013","unstructured":"Guerin E, Man S, Xu P, Kerbel RS (2013) A model of postsurgical advanced metastatic breast cancer more accurately replicates the clinical efficacy of antiangiogenic drugs. Cancer Res 73(9):2743\u20132748","journal-title":"Cancer Res"},{"issue":"166","key":"9677_CR15","doi-asserted-by":"publisher","first-page":"166ra3","DOI":"10.1126\/scitranslmed.3004358","volume":"5","author":"CR Isham","year":"2013","unstructured":"Isham CR, Bossou AR, Negron V et al (2013) Pazopanib enhances paclitaxel-induced mitotic catastrophe in anaplastic thyroid cancer. Sci Transl Med 5(166):166ra3","journal-title":"Sci Transl Med"},{"issue":"17","key":"9677_CR16","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.1200\/JCO.2007.15.7636","volume":"27","author":"A Hauschild","year":"2009","unstructured":"Hauschild A, Agarwala SS, Trefzer U et al (2009) Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 27(17):2823\u20132830","journal-title":"J Clin Oncol"},{"key":"9677_CR17","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S1470-2045(10)70132-7","volume":"11","author":"RS Herbst","year":"2010","unstructured":"Herbst RS, Sun Y, Eberhardt WE et al (2010) Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol 11:619\u2013626","journal-title":"Lancet Oncol"},{"key":"9677_CR18","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1200\/JCO.2010.29.4496","volume":"29","author":"JR Hecht","year":"2011","unstructured":"Hecht JR, Trarbach T, Hainsworth JD et al (2011) Randomized, placebo-controlled, phase II study of first-line oxaliplatin-based chemotherapy plus PTK787\/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma. J Clin Oncol 29:1997\u20132003","journal-title":"J Clin Oncol"},{"issue":"2","key":"9677_CR19","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.clbc.2011.03.005","volume":"11","author":"NJ Robert","year":"2011","unstructured":"Robert NJ, Saleh MN, Paul D et al (2011) Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast vancer: a phase III, randomized, open-label trial. Clin Breast Cancer 11(2):82\u201392","journal-title":"Clin Breast Cancer"},{"key":"9677_CR20","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1200\/JCO.2011.35.7376","volume":"30","author":"J Bergh","year":"2012","unstructured":"Bergh J, Bondarenko IM, Lichinitser MR et al (2012) First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study. J Clin Oncol 30:921\u2013929","journal-title":"J Clin Oncol"},{"key":"9677_CR21","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1038\/bjc.2012.100","volume":"1006","author":"JH Yi","year":"2012","unstructured":"Yi JH, Lee J, Lee J et al (2012) Randomized phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. Br J Cancer 1006:1469\u20131474","journal-title":"Br J Cancer"},{"issue":"10","key":"9677_CR22","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1200\/JCO.2012.45.1930","volume":"31","author":"A Carrato","year":"2013","unstructured":"Carrato A, Swieboda-Sadlej A, Staszewska-Skurczynska M et al (2013) Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial. J Clin Oncol 31(10):1341\u20131347","journal-title":"J Clin Oncol"},{"key":"9677_CR23","doi-asserted-by":"publisher","first-page":"2870","DOI":"10.1200\/JCO.2012.43.3391","volume":"31","author":"JP Crown","year":"2013","unstructured":"Crown JP, Di\u00e9ras V, Staroslawska E et al (2013) Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer. J Clin Oncol 31:2870\u20132878","journal-title":"J Clin Oncol"},{"key":"9677_CR24","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S1470-2045(13)70586-2","volume":"15","author":"M Reck","year":"2014","unstructured":"Reck M, Kaiser R, Mellemgaard A et al (2014) Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol 15:143\u2013155","journal-title":"Lancet Oncol"},{"issue":"12","key":"9677_CR25","doi-asserted-by":"publisher","first-page":"4774","DOI":"10.1158\/0008-5472.CAN-07-6307","volume":"68","author":"F Hilberg","year":"2008","unstructured":"Hilberg F, Roth GJ, Krssak M et al (2008) BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 68(12):4774\u20134782","journal-title":"Cancer Res"},{"issue":"5","key":"9677_CR26","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1158\/1078-0432.CCR-09-2273","volume":"16","author":"BI Rini","year":"2010","unstructured":"Rini BI (2010) New strategies in kidney cancer: therapeutic advances through understanding the molecular basis of response and resistance. Clin Cancer Res 16(5):1348\u20131354","journal-title":"Clin Cancer Res"},{"key":"9677_CR27","doi-asserted-by":"publisher","first-page":"3691","DOI":"10.2147\/OTT.S78805","volume":"8","author":"N Awasthi","year":"2015","unstructured":"Awasthi N, Schwarz RE (2015) Profile of nintedanib in the treatment of solid tumors: the evidence to date. Onco Targets Ther 8:3691\u20133701","journal-title":"Onco Targets Ther"},{"key":"9677_CR28","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.lungcan.2015.08.003","volume":"90","author":"M Reck","year":"2015","unstructured":"Reck M, Mellemgaard A, von Pawel J et al (2015) Anti-angiogenic-specific adverse events in patients with non-small cell lung cancer treated with nintedanib and docetaxel. Lung Cancer 90:267\u2013273","journal-title":"Lung Cancer"},{"key":"9677_CR29","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1093\/annonc\/mdp506","volume":"21","author":"A du Bois","year":"2010","unstructured":"du Bois A, Huober J, Stopfer P et al (2010) A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies. Ann Oncol 21:370\u2013375","journal-title":"Ann Oncol"},{"key":"9677_CR30","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1093\/annonc\/mdr596","volume":"23","author":"RC Doebele","year":"2012","unstructured":"Doebele RC, Conkling P, Traynor AM et al (2012) A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer. Ann Oncol 23:2094\u20132102","journal-title":"Ann Oncol"},{"key":"9677_CR31","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1038\/bjc.2014.397","volume":"111","author":"M Quintela-Fandino","year":"2014","unstructured":"Quintela-Fandino M, Urruticoechea A, Guerra J et al (2014) Phase I clinical trial of nintedanib plus paclitaxel in early HER-2-negative breast cancer (CNIO-BR-01-2010\/GEICAM-2010-10 study). Br J Cancer 111:1060\u20131064","journal-title":"Br J Cancer"},{"issue":"10","key":"9677_CR32","doi-asserted-by":"publisher","first-page":"e0164499","DOI":"10.1371\/journal.pone.0164499","volume":"11","author":"C Schliemann","year":"2016","unstructured":"Schliemann C, Gerss J, Wiebe S et al (2016) A phase I dose escalation study of the triple angiokinase inhibitor nintedanib combined with low-dose cytarabine in elderly patients with acute myeloid leukemia. PLoS ONE 11(10):e0164499. doi: https:\/\/doi.org\/10.1371\/journal.pone.0164499","journal-title":"PLoS ONE"},{"issue":"43","key":"9677_CR33","doi-asserted-by":"publisher","first-page":"17069","DOI":"10.1073\/pnas.0708148104","volume":"104","author":"JM Ebos","year":"2007","unstructured":"Ebos JM, Lee CR, Christensen JG, Mutsaers AJ, Kerbel RS (2007) Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc Natl Acad Sci USA 104(43):17069\u201317074","journal-title":"Proc Natl Acad Sci USA"},{"issue":"14","key":"9677_CR34","doi-asserted-by":"publisher","first-page":"3964","DOI":"10.1093\/emboj\/18.14.3964","volume":"18","author":"T Asahara","year":"1999","unstructured":"Asahara T, Takahashi T, Masuda H et al (1999) VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J 18(14):3964\u20133972","journal-title":"EMBO J"},{"key":"9677_CR35","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1161\/01.ATV.0000151690.43777.e4","volume":"25","author":"TM Powell","year":"2005","unstructured":"Powell TM, Paul JD, Hill JM et al (2005) Granulocyte colony-stimulating factor mobilizes functional endothelial progenitor cells in patients with coronary artery disease. Arterioscler Thromb Vasc Biol 25:296\u2013301","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"5","key":"9677_CR36","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/nm1400","volume":"12","author":"DK Jin","year":"2006","unstructured":"Jin DK, Shido K, Kopp H-G et al (2006) Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4 + hemangiocytes. Nat Med 12(5):557\u2013567","journal-title":"Nat Med"},{"key":"9677_CR37","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.cell.2005.10.036","volume":"124","author":"M Grunewald","year":"2006","unstructured":"Grunewald M, Avraham I, Dor Y et al (2006) VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell 124:175\u2013189","journal-title":"Cell"},{"issue":"2","key":"9677_CR38","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1385\/IR:23:2-3:263","volume":"23","author":"JE Ohm","year":"2001","unstructured":"Ohm JE, Carbone DP (2001) VEGF as a mediator of tumor-associated immunodeficiency. Immunol Res 23(2):263\u2013272","journal-title":"Immunol Res"},{"key":"9677_CR39","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/nri3064","volume":"11","author":"GT Motz","year":"2011","unstructured":"Motz GT, Coukos G (2011) The parallel lives of angiogenesis and immunosuppression: cancer and other tales. Nat Rev Immunol 11:702\u2013711","journal-title":"Nat Rev Immunol"},{"key":"9677_CR40","doi-asserted-by":"publisher","first-page":"202","DOI":"10.3389\/fonc.2015.00202","volume":"5","author":"PA Ott","year":"2015","unstructured":"Ott PA, Hodi FS, Buchbinder EI (2015) Inhibition of immune checkpoints and vascular endothelial growth factor as combination therapy for metastatic melanoma: an overview of rationale, preclinical evidence, and initial clinical data. Front Oncol 5:202","journal-title":"Front Oncol"},{"key":"9677_CR41","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1096\/fj.14-250985","volume":"29","author":"H Huang","year":"2015","unstructured":"Huang H, Langenkamp E, Georganaki M et al. (2015) VEGF suppresses T-lymphocyte infiltration in the tumor microenvironment through inhibition of NF-kB-induced endothelial activation. FASEB J 29:227\u201338","journal-title":"FASEB J"},{"issue":"1","key":"9677_CR42","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.clim.2009.11.013","volume":"135","author":"Y Gu","year":"2010","unstructured":"Gu Y, Zhao W, Meng F et al (2010) Sunitinib impairs the proliferation and function of human peripheral T cell and prevents T-cell-mediated immune response in mice. Clin Immunol 135(1):55\u201362","journal-title":"Clin Immunol"},{"issue":"13","key":"9677_CR43","doi-asserted-by":"publisher","first-page":"3951","DOI":"10.1158\/1078-0432.CCR-07-0374","volume":"13","author":"EA Manning","year":"2007","unstructured":"Manning EA, Ullman JGM, Leatherman JM et al (2007) A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism. Clin Cancer Res 13(13):3951\u20133959","journal-title":"Clin Cancer Res"},{"issue":"7","key":"9677_CR44","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1158\/2326-6066.CIR-14-0053","volume":"2","author":"FS Hodi","year":"2014","unstructured":"Hodi FS, Lawrence D, Lezcano C et al (2014) Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol Res 2(7):632\u2013642","journal-title":"Cancer Immunol Res"},{"issue":"4","key":"9677_CR45","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/ijc.25113","volume":"127","author":"M van Dongen","year":"2010","unstructured":"van Dongen M, Savage ND, Jordanova ES et al (2010) Anti-inflammatory M2 type macrophages characterize metastasized and tyrosine kinase inhibitor-treated gastrointestinal stromal tumors. Int J Cancer 127(4):899\u2013909","journal-title":"Int J Cancer"},{"key":"9677_CR46","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s00281-013-0367-7","volume":"35","author":"SK Biswas","year":"2013","unstructured":"Biswas SK, Allavena P, Mantovani A (2013) Tumor-associated macrophages: functional diversity, clinical significance, and open questions. Semin Immunopathol 35:585\u2013600","journal-title":"Semin Immunopathol"},{"issue":"43","key":"9677_CR47","doi-asserted-by":"publisher","first-page":"17561","DOI":"10.1073\/pnas.1215397109","volume":"109","author":"Y Huang","year":"2012","unstructured":"Huang Y, Yuan J, Righi E et al (2012) Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci USA 109(43):17561\u201317566","journal-title":"Proc Natl Acad Sci USA"},{"key":"9677_CR48","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1126\/science.1127592","volume":"313","author":"Y Shaked","year":"2006","unstructured":"Shaked Y, Ciarrocchi A, Franco M et al (2006) Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 313:1785\u20131787","journal-title":"Science"},{"key":"9677_CR49","first-page":"5209","volume":"59","author":"M Prewett","year":"1999","unstructured":"Prewett M, Huber J, Li Y et al (1999) Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res 59:5209\u20135218","journal-title":"Cancer Res"},{"key":"9677_CR50","doi-asserted-by":"publisher","first-page":"6616","DOI":"10.1158\/0008-5472.CAN-04-0401","volume":"64","author":"G Bocci","year":"2004","unstructured":"Bocci G, Man S, Green SK et al (2004) ) Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies. Cancer Res 64:6616\u20136625","journal-title":"Cancer Res"},{"key":"9677_CR51","doi-asserted-by":"publisher","first-page":"5398","DOI":"10.4049\/jimmunol.166.9.5398","volume":"166","author":"DI Gabrilovich","year":"2001","unstructured":"Gabrilovich DI, Velders MP, Sotomayor EM, Kast VM (2001) Mechanism of immune dysfunction in cancer mediated by immature Gr-1 + myeloid cells. J Immunol 166:5398\u20135406","journal-title":"J Immunol"},{"key":"9677_CR52","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3389\/fimmu.2015.00067","volume":"6","author":"C Germain","year":"2015","unstructured":"Germain C, Gnjatic S, Dieu-Nosjean M-C (2015) Tertiary lymphoid structure-associated B cells are key players in anti-tumor immunity. Front Immunol 6:67","journal-title":"Front Immunol"},{"key":"9677_CR53","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/s12967-015-0567-0","volume":"13","author":"E Muraro","year":"2015","unstructured":"Muraro E, Comaro E, Talamini R et al (2015) Improved natural killer cell activity and retained anti-tumor CD8 + T cell responses contribute to the induction of a pathological complete response in HER2-positive breast cancer patients undergoing neoadjuvant chemotherapy. J Transl Med 13:204","journal-title":"J Transl Med"},{"key":"9677_CR54","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/S0192-0561(00)00024-2","volume":"22","author":"M Lee","year":"2000","unstructured":"Lee M, Yea SS, Jeon YJ (2000) Paclitaxel causes mouse splenic lymphocytes to a state hyporesponsive to lipopolysaccharide stimulation. Int J Immunopharmacol 22:615\u2013621","journal-title":"Int J Immunopharmacol"},{"key":"9677_CR55","first-page":"241","volume":"58","author":"SF Amato","year":"1998","unstructured":"Amato SF, Swart JM, Berg M, Wanebo HJ, Mehta SR, Chiles TC (1998) Transient stimulation of the c-Jun-NH2-terminal kinase\/activator protein 1 pathway and inhibition of extracellular signal-regulated kinase are early effects in paclitaxel-mediated apoptosis in human B lymphoblasts. Cancer Res 58:241\u2013247","journal-title":"Cancer Res"},{"issue":"19","key":"9677_CR56","doi-asserted-by":"publisher","first-page":"30644","DOI":"10.18632\/oncotarget.16141","volume":"8","author":"F M\u00fcller","year":"2017","unstructured":"M\u00fcller F, Stookey S, Cunningham T, Pastan I (2017) Paclitaxel synergizes with exposure time adjusted CD22-targeting immunotoxins against B-cell malignancies. Oncotarget 8(19):30644\u201330655","journal-title":"Oncotarget"},{"key":"9677_CR57","doi-asserted-by":"publisher","first-page":"45682","DOI":"10.1038\/srep45682","volume":"7","author":"WK Nevala","year":"2017","unstructured":"Nevala WK, Butterfield JT, Sutor SL, Knauer DJ, Markovic SN (2017) Antibody-targeted paclitaxel loaded nanoparticles for the treatment of CD20 + B-cell lymphoma. Sci Rep 7:45682. DOI: https:\/\/doi.org\/10.1038\/srep45682","journal-title":"Sci Rep"},{"key":"9677_CR58","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/S0140-6736(15)01088-0","volume":"388","author":"GC Jayson","year":"2016","unstructured":"Jayson GC, Kerbel R, Ellis LM, Harris AL (2016) Antiangiogenic therapy in oncology: current status and future directions. Lancet 388:518\u2013529","journal-title":"Lancet"},{"issue":"11","key":"9677_CR59","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1016\/j.yexcr.2013.03.007","volume":"319","author":"T Voloshin","year":"2013","unstructured":"Voloshin T, Voest EE, Shaked Y (2013) The host immunological response to cancer therapy: an emerging concept in tumor biology. Exp Cell Res 319(11):1687\u20131695","journal-title":"Exp Cell Res"},{"key":"9677_CR60","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1038\/sj.bjc.6605366","volume":"101","author":"R Kumar","year":"2009","unstructured":"Kumar R, Crouthamel M-C, Rominger DH et al (2009) Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors. Br J Cancer 101:1717\u20131723","journal-title":"Br J Cancer"},{"key":"9677_CR61","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/nature00821","volume":"417","author":"H-P Gerber","year":"2002","unstructured":"Gerber H-P, Malik AK, Solar GP (2002) VEGF regulates hematopoietic stem cell survival by an internal autocrine loop mechanism. Nature 417:954\u2013958","journal-title":"Nature"},{"issue":"9","key":"9677_CR62","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1097\/JTO.0b013e3181e59c24","volume":"5","author":"SV Novitskiy","year":"2010","unstructured":"Novitskiy SV, Csiki I, Huang Y et al (2010) Anti-vascular endothelial growth factor treatment in combination with chemotherapy delays hematopoietic recovery due to decreased proliferation of bone marrow hematopoietic progenitor cells. J Thorac Oncol 5(9):1410\u20131415","journal-title":"J Thorac Oncol"},{"key":"9677_CR63","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1038\/nrc2444","volume":"8","author":"C Murdoch","year":"2008","unstructured":"Murdoch C, Muthana M, Coffelt SB, Lewis CE (2008) The role of myeloid cells in the promotion of tumor angiogenesis. Nat Rev Cancer 8:618\u2013631","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"9677_CR64","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/j.celrep.2017.10.104","volume":"21","author":"E Hawila","year":"2017","unstructured":"Hawila E, Razon H, Wildbaum G et al (2017) CCR5 directs the mobilization of CD11b + Gr1 + Ly6Clow polymorphonuclear myeloid cells from the bone marrow to the blood to support tumor development. Cell Rep 21(8):2212\u20132222","journal-title":"Cell Rep"},{"issue":"6","key":"9677_CR65","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1158\/1078-0432.CCR-08-1332","volume":"15","author":"JS Ko","year":"2009","unstructured":"Ko JS, Zea AH, Rini BI et al (2009) Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 15(6):2148\u20132156","journal-title":"Clin Cancer Res"},{"issue":"9","key":"9677_CR66","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1002\/ijc.25863","volume":"129","author":"A Bose","year":"2011","unstructured":"Bose A, Taylor JL, Alber S et al (2011) Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination. Int J Cancer 129(9):2158\u20132170","journal-title":"Int J Cancer"},{"issue":"3","key":"9677_CR67","doi-asserted-by":"publisher","first-page":"e989764","DOI":"10.4161\/2162402X.2014.989764","volume":"4","author":"O Draghiciu","year":"2015","unstructured":"Draghiciu O, Nijman HW, Hoogeboom BN, Meijerhof T, Daemen T (2015) Sunitinib depletes myeloid-derived suppressor cells and synergizes with cancer vaccine to enhance antigen-specific immune responses and tumor eradication. OncoImmunology 4(3):e989764","journal-title":"OncoImmunology"},{"issue":"10","key":"9677_CR68","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1007\/s00262-015-1735-z","volume":"64","author":"A Guislain","year":"2015","unstructured":"Guislain A, Gadiot J, Kaiser A et al (2015) Sunitinib pretreatment improves tumor-infiltrating lymphocyte expansion by reduction of intratumoral content of myeloid-derived suppressor cells in human renal cell carcinoma. Cancer Immunol Immunother 64(10):1241\u20131250","journal-title":"Cancer Immunol Immunother"},{"issue":"9","key":"9677_CR69","doi-asserted-by":"publisher","first-page":"3526","DOI":"10.1158\/0008-5472.CAN-09-3278","volume":"70","author":"JS Ko","year":"2010","unstructured":"Ko JS, Rayman P, Ireland J et al (2010) Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. Cancer Res 70(9):3526\u20133536","journal-title":"Cancer Res"},{"issue":"7","key":"9677_CR70","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.intimp.2011.01.030","volume":"11","author":"J Finke","year":"2011","unstructured":"Finke J, Ko J, Rini B, Rayman P, Ireland J, Cohen P (2011) MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy. Int Immunopharmacol 11(7):853\u2013858","journal-title":"Int Immunopharmacol"},{"issue":"6","key":"9677_CR71","doi-asserted-by":"publisher","first-page":"e1316437","DOI":"10.1080\/2162402X.2017.1316437","volume":"6","author":"C Secondini","year":"2017","unstructured":"Secondini C, Coquoz O, Spagnuolo L et al (2017) Arginase inhibition suppresses lung metastasis in the 4T1 breast cancer model independently of the immunomodulatory and anti-metastatic effects of VEGFR-2 blockade. Oncoimmunology 6(6):e1316437","journal-title":"Oncoimmunology"},{"key":"9677_CR72","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s00262-016-1941-3","volume":"66","author":"AA Thomas","year":"2017","unstructured":"Thomas AA, Fisher JL, Hampton TH et al (2017) Immune modulation associated with vascular endothelial growth factor (VEGF) blockade in patients with glioblastoma. Cancer Immunol Immunother 66:379\u2013389","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"9677_CR73","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1158\/0008-5472.CAN-08-1921","volume":"69","author":"PC Rodriguez","year":"2009","unstructured":"Rodriguez PC, Ernstoff MS, Hernandez C et al (2009) Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res 69(4):1553\u20131560","journal-title":"Cancer Res"},{"key":"9677_CR74","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neo.2016.11.010","volume":"19","author":"L Deng","year":"2017","unstructured":"Deng L, Stafford JH, Liu SC et al (2017) SDF-1 blockade enhances anti-VEGF therapy of glioblastoma and can be monitored by MRI. Neoplasia 19:1\u20137","journal-title":"Neoplasia"},{"issue":"7","key":"9677_CR75","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1158\/1535-7163.MCT-09-0280","volume":"8","author":"CL Roland","year":"2009","unstructured":"Roland CL, Dineen SP, Lynn KD et al (2009) Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts. Mol Cancer Ther 8(7):1761\u20131771","journal-title":"Mol Cancer Ther"},{"key":"9677_CR76","doi-asserted-by":"publisher","first-page":"3420","DOI":"10.1158\/1078-0432.CCR-09-2904","volume":"16","author":"W Zhang","year":"2010","unstructured":"Zhang W, Zhu XD, Sun HC et al (2010) Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects. Clin Cancer Res 16:3420\u20133430","journal-title":"Clin Cancer Res"},{"key":"9677_CR77","doi-asserted-by":"publisher","unstructured":"Sunay MM, Leatherman JM, Chen G, Emens LA (2013) Sorafenib modulates macrophages to promote T helper type 1 immunity. In: Proceedings of the 104th annual meeting of the American Association for Cancer Research, Apr 6\u201310, 2013. AACR, Washington, DC, Philadelphia; Cancer Res 73(8 Suppl): Abstract nr 3985. doi: https:\/\/doi.org\/10.1158\/1538-7445.AM2013-3985","DOI":"10.1158\/1538-7445.AM2013-3985"},{"issue":"3","key":"9677_CR78","first-page":"893","volume":"32","author":"M Kogan","year":"2012","unstructured":"Kogan M, Fischer-Smith T, Kaminsky R, Lehmicke G, Rappaport J (2012) CSF-1R up-regulation is associated with response to pharmacotherapy targeting tyrosine kinase activity in AML cell lines. Anticancer Res 32(3):893\u2013899","journal-title":"Anticancer Res"},{"key":"9677_CR79","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/nrc2868","volume":"10","author":"AS Chung","year":"2010","unstructured":"Chung AS, Lee J, Ferrara N (2010) Targeting the tumor vasculature: insights from physiological angiogenesis. Nat Rev Cancer 10:505\u2013514","journal-title":"Nat Rev Cancer"},{"issue":"57","key":"9677_CR80","doi-asserted-by":"publisher","first-page":"96496","DOI":"10.18632\/oncotarget.20410","volume":"8","author":"YA Lyons","year":"2017","unstructured":"Lyons YA, Pradeep S, Wu SY et al (2017) Macrophage depletion through colony stimulating factor 1 receptor pathway blockade overcomes adaptive resistance to anti-VEGF therapy. Oncotarget 8(57):96496\u201396505","journal-title":"Oncotarget"},{"key":"9677_CR81","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1159\/000320609","volume":"79","author":"M Manzoni","year":"2010","unstructured":"Manzoni M, Rovati B, Ronzoni M et al (2010) Immunological effects of bevacizumab-based treatment in metastatic colorectal cancer. Oncology 79:187\u2013196","journal-title":"Oncology"},{"issue":"5","key":"9677_CR82","doi-asserted-by":"publisher","first-page":"e24436","DOI":"10.4161\/onci.24436","volume":"2","author":"AS Mansfield","year":"2013","unstructured":"Mansfield AS, Nevala WK, Lieser EAT, Leontovich AA, Markovic SN (2013) The immunomodulatory effects of bevacizumab on systemic immunity in patients with metastatic melanoma. OncoImmunology 2(5):e24436","journal-title":"OncoImmunology"},{"key":"9677_CR83","doi-asserted-by":"publisher","first-page":"16025","DOI":"10.1038\/cddiscovery.2016.25","volume":"2","author":"EC Martino","year":"2016","unstructured":"Martino EC, Misso G, Pastina P et al (2016) Immune-modulating effects of bevacizumab in metastatic non-small-cell lung cancer patients. Cell Death Discov 2:16025","journal-title":"Cell Death Discov"},{"key":"9677_CR84","doi-asserted-by":"publisher","first-page":"12624","DOI":"10.1038\/ncomms12624","volume":"7","author":"JJ Wallin","year":"2016","unstructured":"Wallin JJ, Bendell JC, Funke R et al (2016) Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma. Nat Commun 7:12624","journal-title":"Nat Commun"},{"issue":"10","key":"9677_CR85","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1158\/2326-6066.CIR-16-0084","volume":"4","author":"X Wu","year":"2016","unstructured":"Wu X, Giobbie-Hurder A, Liao X et al (2016) VEGF neutralization plus CTLA-4 blockade alters soluble and cellular factors associated with enhancing lymphocyte infiltration and humoral recognition in melanoma. Cancer Immunol Res 4(10):858\u2013868","journal-title":"Cancer Immunol Res"},{"issue":"7","key":"9677_CR86","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/j.jtho.2018.03.032","volume":"13","author":"P-H Feng","year":"2018","unstructured":"Feng P-H, Chen K-Y, Huang Y-C et al (2018) Bevacizumab reduces S100A9-positive MDSCs linked to intracranial control in patients with EGFR-mutant lung adenocarcinoma. J Thorac Oncol 13(7):958\u2013967","journal-title":"J Thorac Oncol"},{"issue":"23","key":"9677_CR87","doi-asserted-by":"publisher","first-page":"16334","DOI":"10.1074\/jbc.M112.437962","volume":"288","author":"F Stehle","year":"2013","unstructured":"Stehle F (2013) Reduced immunosuppressive properties of axitinib in comparison with other tyrosine kinase inhibitors. J Biol Chem 288(23):16334 \u2013 47","journal-title":"J Biol Chem"},{"issue":"8","key":"9677_CR88","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1002\/ijc.26219","volume":"130","author":"B Farsaci","year":"2012","unstructured":"Farsaci B, Higgins JP, Hodge JW (2012) Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy. Int J Cancer 130(8):1948\u20131959","journal-title":"Int J Cancer"},{"issue":"6","key":"9677_CR89","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.1158\/0008-5472.CAN-08-4709","volume":"69","author":"J Ozao-Choy","year":"2009","unstructured":"Ozao-Choy J, Ma G, Kao J et al (2009) The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res 69(6):2514\u20132522","journal-title":"Cancer Res"},{"issue":"2","key":"9677_CR90","doi-asserted-by":"publisher","first-page":"104","DOI":"10.2174\/157489112801619719","volume":"7","author":"M Santoni","year":"2012","unstructured":"Santoni M, Rizzo M, Burattini L et al (2012) Present and future of tyrosine kinase inhibitors in renal cell carcinoma: analysis of hematologic toxicity. Recent Pat Antiinfect Drug Discov 7(2):104\u2013110","journal-title":"Recent Pat Antiinfect Drug Discov"},{"issue":"48","key":"9677_CR91","doi-asserted-by":"publisher","first-page":"E6644","DOI":"10.1073\/pnas.1514191112","volume":"112","author":"MND Svensson","year":"2015","unstructured":"Svensson MND, Andersson KME, Was\u00e9n C et al (2015) Murine germinal center B cells require functional Fms-like tyrosine kinase 3 signaling for IgG1 class-switch recombination. Proc Natl Acad Sci USA 112(48):E6644\u2013E6653","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Angiogenesis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10456-019-09677-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10456-019-09677-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10456-019-09677-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T17:47:21Z","timestamp":1721670441000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10456-019-09677-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,28]]},"references-count":91,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["9677"],"URL":"https:\/\/doi.org\/10.1007\/s10456-019-09677-x","relation":{},"ISSN":["0969-6970","1573-7209"],"issn-type":[{"type":"print","value":"0969-6970"},{"type":"electronic","value":"1573-7209"}],"subject":[],"published":{"date-parts":[[2019,8,28]]},"assertion":[{"value":"25 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"FH works for Boehringer Ingelheim RCV, Vienna, Austria. The other authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All applicable international, national, and\/or institutional guidelines for the care and use of animals were followed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}